

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders.
In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

[Translation]

(Securities Code 4503)

June 19, 2025

To: Shareholders

Notice of Resolutions Adopted at the 20th Term Annual Shareholders Meeting

Dear Madam/Sir:

You are hereby notified that at the 20th Term Annual Shareholders Meeting of Astellas Pharma Inc. (the “Company”) held today, the following reports and resolutions were made.

Yours faithfully,

By: Naoki Okamura
Representative Director,
President and CEO
Astellas Pharma Inc.
2-5-1, Nihonbashi-Honcho, Chuo-ku
Tokyo, Japan

Particulars

Matters reported:

1. Report on the Business Report, Consolidated Financial Statements and Financial Statements for the 20th Term Business Year (from April 1, 2024 to March 31, 2025);
2. Report on the Results of Audit by Financial Auditor and the Audit & Supervisory Committee for Consolidated Financial Statements for the 20th Term Business Year (from April 1, 2024 to March 31, 2025)

The above matters were reported.

Matters resolved:

First Proposal: Election of Nine (9) Directors (Excluding Directors Who Are Audit & Supervisory Committee Members)

This proposal was approved as originally proposed, and the nine (9) candidates, Dr. Kenji Yasukawa, Mr. Naoki Okamura, Mr. Katsuyoshi Sugita, Mr. Takashi Tanaka, Ms. Eriko Sakurai, Mr. Masahiro Miyazaki, Dr. Yoichi Ohno, Dr. Andreas Busch and Mr. Mark Enyedy were elected as Directors (excluding Directors who are Audit & Supervisory Committee Members) and they assumed their offices.

Mr. Takashi Tanaka, Ms. Eriko Sakurai, Mr. Masahiro Miyazaki, Dr. Yoichi Ohno, Dr. Andreas Busch and Mr. Mark Enyedy are outside Directors.

Second Proposal: Election of One (1) Director Who Is an Audit & Supervisory Committee Member

This proposal was approved as originally proposed, and the candidate, Ms. Rie Akiyama was elected as a Director who is an Audit & Supervisory Committee Member and she assumed her office.

Ms. Rie Akiyama is an outside Director.

Third Proposal: Revision of the Amount of Remuneration for Outside Directors (Excluding Directors Who Are Audit & Supervisory Committee Members)

This proposal was approved as originally proposed, and the amount of basic remuneration was revised to be paid to outside Directors (excluding Directors who are Audit & Supervisory Committee

Members) to be no more than ¥250 million per year.

- End -

(Reference)

Directors of the Company after the close of this Annual Shareholders Meeting are as follows:

Representative Director, Chairman of the Board	Kenji Yasukawa
Representative Director, President and CEO	Naoki Okamura
Representative Director, Executive Vice President	Katsuyoshi Sugita
Director	Takashi Tanaka
Director	Eriko Sakurai
Director	Masahiro Miyazaki
Director	Yoichi Ohno
Director	Andreas Busch
Director	Mark Enyedy
Director (Audit & Supervisory Committee Member)	Rika Hirota
Director (Audit & Supervisory Committee Member)	Mika Nakayama
Director (Audit & Supervisory Committee Member)	Rie Akiyama
Director (Audit & Supervisory Committee Member)	Tomoko Aramaki

(Note) Mr. Takashi Tanaka, Ms. Eriko Sakurai, Mr. Masahiro Miyazaki, Dr. Yoichi Ohno, Dr. Andreas Busch, Mr. Mark Enyedy, Ms. Mika Nakayama, Ms. Rie Akiyama and Ms. Tomoko Aramaki are outside Directors, and they are independent directors stipulated by Tokyo Stock Exchange, Inc.

- End -